The Aporia · GSK sees falling vaccine sales take shine off earnings

GSK sees falling vaccine sales take shine off earnings

Read the original at Evening Standard ↗

Cite

APA MLA Chicago

Williams, H. (2026, October 28). GSK sees falling vaccine sales take shine off earnings. Evening Standard. https://www.standard.co.uk/business/business-news/gsk-british-aj-bell-cambridge-stevenage-b1302631.html

Dated from the outlet's own feed. Check the original for its byline.

Quick Summary

GSK reported a drop in vaccine sales to £2.6 billion for the third quarter ending September 30, down from previous quarters due to reduced demand for its Shingrix and Arexvy vaccines. Despite this, core operating profits rose by 5% to £3.08 billion, surpassing market expectations of £2.93 billion on a constant currency basis. However, pre-tax profits declined to £1.94 billion from £2.5 billion the previous year. GSK's CEO, Luke Miels, faces challenges in developing new drugs to counteract the impending patent expiration for its HIV drug Dolutegravir and is implementing cost-cutting measures across research and development and support services roles.

Written by AI on 2026-10-28, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

As of October 28, 2026, GSK reported a decline in vaccine sales by 2% to £2.6 billion for the quarter ending September 30, primarily due to reduced demand for its shingles vaccine Shingrix and respiratory virus shot Arexvy. Despite this, core operating profits rose by 5% to £3.08 billion, outperforming market expectations of £2.93 billion. However, pre-tax profits dropped to £1.94 billion from £2.5 billion the previous year. The company's stock price fell by 7% in morning trading as a result of the disappointing vaccine sales figures. Luke Miels, GSK’s CEO, emphasized focus on operational delivery and R&D acceleration to counteract upcoming patent expirations, particularly for its key HIV treatment dolutegravir.

Written for “GSK Earnings Report” on 2026-11-04, grounded in this article and the 0 other(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Signals How these are calculated →

Claims extracted

sentences that state something as happening or true

Uncertain

0 of 11 hedged ("reportedly", "may", "according to")

Leaning

not political

takes no side on a contested political question

Publisher signals

64/100

Evening Standard's corrections and hedging, across everything collected from it. Not a measure of accuracy.

Outlets on this story

Economy/Business

Same framing elsewhere

articles that frame the event the way this one does

Who wrote this

Holly Williams

102 article(s) here · 1 carrying a prediction

🔮 The telecoms giant said the bulk of the cost savings – about £300 million – will come from job cuts among its 16,000-strong workforce in the UK, with aims to reduce its staff costs by around 30%.

2026-11-03 · assertive framing · Virgin Media O2 cutting thousands of jobs in cost savings overhaul

🔮 The Leeds-based group said Mr Potts would take on the role with immediate effect, with current boss Allan Leighton becoming non-executive chairman, two years after he returned to head the firm.

2026-11-03 · assertive framing · Asda bags former Morrisons boss David Potts as new chief executive

2026-11-03 · assertive framing · Virgin Media O2 cutting thousands of jobs in cost savings overhaul

🔮 The group said Mr Potts would take on the role with immediate effect, with current boss Allan Leighton becoming non-executive chairman, two years after he returned to head the firm.

2026-11-03 · assertive framing · Asda bags former Morrisons boss David Potts as new chief executive

2026-11-03 · assertive framing · Virgin Media O2 cutting thousands of jobs in cost savings overhaul

🔮 The telecoms giant said the bulk of the cost savings – about £300 million – will come from job cuts among its 16,000-strong workforce in the UK, with aims to reduce its labour costs by around 30%.

2026-11-03 · assertive framing · Virgin Media O2 cutting thousands of jobs in cost savings overhaul

🔮 The Bank of England is widely expected to hike interest rates on Thursday to 4% from 3.75% given rising UK inflation, but lower oil prices could see policymakers rein in their signals for future rises.

2026-11-02 · mixed framing · Oil prices pull back sharply on signs of US-Iran diplomacy to end war

🔮 Mr Mackenzie will stand down at the end of February after leading Britain’s second biggest pub chain for nearly eight years.

2026-11-02 · assertive framing · Greene King appoints first female chief as long-standing boss stands down

🔮 The oil major agreed the sale of a 65% holding in Castrol to US investment firm Stonepeak in December last year and will retain the remaining 35% stake in a new joint venture.

2026-11-02 · assertive framing · BP nets £4.4bn boost for balance sheet after Castrol deal completes

🔮 Speaking at the group’s Chessington World of Adventures Resort hotel outside London, he told the Press Association the sector’s room key technology systems were robust and security failures would be caused only by “human error”.

2026-11-02 · assertive framing · Travelodge keycard case ‘risks damaging sector’s reputation’ – Merlin executive

Also by Holly Williams

Virgin Media O2 cutting thousands of jobs in cost savings overhaul

2026-11-03 · Evening Standard

Asda bags former Morrisons boss David Potts as new chief executive

2026-11-03 · Evening Standard

Virgin Media O2 cutting thousands of jobs in cost savings overhaul

2026-11-03 · Evening Standard

Asda bags former Morrisons boss David Potts as new chief executive

2026-11-03 · Evening Standard

Nothing else under this byline is closely related to this article, so these are simply their most recent.

All 102 articles by Holly Williams →

Narrative

Claims (11 extracted, 0 hedged)

GSK sees falling vaccine sales take shine off earnings The British pharmaceutical firm revealed vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles jab Shingrix and Arexvy shot for the respiratory virus RSV. asserted

demand → see → virus

Shares in the FTSE 100 group fell 7% in morning trading on Wednesday on the sales disappointment. asserted

Shares → fall → disappointment

This came despite GSK posting a 5% rise in core operating profits, excluding exceptional items and currency movements, to £3.08 billion for the third quarter, against the £2.93 billion expected in the market, as sales on a constant currency basis lifted 5%. asserted

sales → come → basis

The results showed sales of Shingrix fell 5% and Arexy tumbled 24% amid lower US sales. asserted

Arexy → show → sales

Earnings were helped higher by sales of speciality medicines, up 15% in the quarter, as well as cancer treatments, which jumped 23%. asserted

which → help → quarter

Luke Miels, chief executive of GSK, said: “We remain focused on operational delivery, execution and accelerating research and development.” asserted

We → say → research

He said: “Chief executive Luke Miels is under pressure to build up a pipeline of new drugs ahead of a patent cliff with the loss of exclusivity on its blockbuster HIV drug Dolutegravir. asserted

Miels → say → drug

“Miels has made progress on this front, reflected in the strong showing for the speciality medicines arm and recent reporting around a big increase in its cancer treatment pipeline, and is continuing to bring down costs throughout the business. asserted

Miels → make → business

“However, the latest update is a reminder Miels still has plenty of work to do.” asserted

Miels → do → work

GSK revealed in first half results in July that annual costs are set to be cut by £1.9 billion over the next three years to fund investment, ramp up R&D and help offset the hit when one of its key HIV treatments, dolutegravir, comes off its patent. asserted

one → reveal → patent

In February, it confirmed around 350 R&D jobs were going across the US and UK and in July it said some support services roles were being impacted by cost cutting, but did not reveal numbers. asserted

roles → confirm → numbers

GSK sees falling vaccine sales take shine off earnings

Quick Summary

AI analysis

Story

Compared with similar articles

Signals How these are calculated →

How this is being covered How these are calculated →

Publisher

Who wrote this

Topics

Subjects

Narrative

Claims (11 extracted, 0 hedged)